Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-10-30

Clinical Trial Update: Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial update on efficacy and safety of FTY720 (fingolimod) in relapsing multiple sclerosis completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FTY720 (fingolimod)

Snippet

Sponsor: Novartis | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2012-10-30